These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 30659852

  • 1. The tralokinumab story: Nothing is ever simple.
    Apter AJ.
    J Allergy Clin Immunol; 2019 Apr; 143(4):1336-1338. PubMed ID: 30659852
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program.
    Panettieri RA, Wang M, Braddock M, Bowen K, Colice G.
    Immunotherapy; 2018 Mar 01; 10(6):473-490. PubMed ID: 29536781
    [Abstract] [Full Text] [Related]

  • 4. The Safety and Efficacy of Anti-IL-13 Treatment with Tralokinumab (CAT-354) in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis.
    Zhang Y, Cheng J, Li Y, He R, Pan P, Su X, Hu C.
    J Allergy Clin Immunol Pract; 2019 Mar 01; 7(8):2661-2671.e3. PubMed ID: 31152798
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
    Bagnasco D, Ferrando M, Varricchi G, Passalacqua G, Canonica GW.
    Int Arch Allergy Immunol; 2016 Mar 01; 170(2):122-31. PubMed ID: 27637004
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.
    De Boever EH, Ashman C, Cahn AP, Locantore NW, Overend P, Pouliquen IJ, Serone AP, Wright TJ, Jenkins MM, Panesar IS, Thiagarajah SS, Wenzel SE.
    J Allergy Clin Immunol; 2014 Apr 01; 133(4):989-96. PubMed ID: 24582316
    [Abstract] [Full Text] [Related]

  • 16. Farewell.
    Roberts G.
    Clin Exp Allergy; 2020 Dec 01; 50(12):1284-1286. PubMed ID: 33283365
    [No Abstract] [Full Text] [Related]

  • 17. Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history.
    Corren J, Castro M, Ford LB, Bernstein JA, Jayawardena S, Maroni J, Rowe P, Amin N, Pirozzi G, Graham NMH, Khan A, Eckert L, Teper A.
    Ann Allergy Asthma Immunol; 2019 Aug 01; 123(2):222-224.e1. PubMed ID: 31075309
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.